tag cancer-immunotherapy 
pharmaphorum
JANUARY 5, 2021
The FDA’s breakthrough status is for tiragolumab plus Tecentriq is the first for a TIGIT drug, and covers the first-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) that expresses high levels of PD-L1. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.
Rethinking Clinical Trials
MARCH 1, 2023
S1800A was a Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for NSCLC patients previously treated with immunotherapy performed within the Lung-MAP platform. They are both approved and used widely in lung cancer, and combining two existing agents is logistically and clinically simpler.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 5, 2022
The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. The post FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag appeared first on. Preliminary results from that study showed a 53.8%
Drug Discovery World
JANUARY 9, 2023
In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain cancer glioblastoma, with promising results. The findings are published in Science Translational Medicine. . CRISPR-Cas9 gene editing .
XTalks
JANUARY 28, 2022
Kimmtrak is part of a novel class of bispecific T cell immunotherapies being developed by Immunocore. Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. Related: Cancer Blood Test Developed by University of Oxford Researchers Can Detect Metastasis. The median treatment time is about 23 weeks (or 5.3
pharmaphorum
JANUARY 11, 2021
While bluebird has conducted pioneering work in gene therapy for blood disorders and in cancer cell therapy, products have been delayed by issues with filing data for the FDA. million price tag. Zynteglo is already in beta-thalassemia in Europe, where the company will seek to expand access despite its hefty $1.8
XTalks
FEBRUARY 27, 2024
Melanoma is a type of skin cancer often caused by exposure to ultraviolet light, such as that from sunlight or indoor tanning. Despite accounting for only about one percent of all skin cancers, melanomas make up a significant proportion of cancer-related deaths. The cost is the highest of any cell-based cancer drug in the US.
Expert insights. Personalized for you.
52 
Let's personalize your content